camoteskimab (AVTX-007) / Avalo Therap, AstraZeneca, Apollo Therap - LARVOL DELTA

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=62 | Active, not recruiting | Sponsor: Apollo Therapeutics Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Apollo Therapeutics Ltd

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=13 | Completed | Sponsor: Avalo Therapeutics, Inc. | Phase classification: P1b ➔ P1

Phase classification • Hematological Malignancies • Multiple Myeloma • Oncology

A Study to Evaluate Camoteskimab in Participants With Still's Disease (clinicaltrials.gov) - P1b | N=5 | Terminated | Sponsor: Apollo Therapeutics Ltd | Phase classification: P1b/2a ➔ P1b | N=20 ➔ 5 | Recruiting ➔ Terminated; Sponsor discretion

Enrollment change • Phase classification • Trial termination • Immunology • CRP

A Study to Evaluate Camoteskimab in Participants With Still's Disease (AOSD/sJIA) (clinicaltrials.gov) - P1b/2a | N=20 | Recruiting | Sponsor: Apollo Therapeutics Ltd | Phase classification: P1b ➔ P1b/2a | N=12 ➔ 20 | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Sep 2023 ➔ Dec 2024

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Idiopathic Arthritis • Immunology • Rheumatology • CRP • IL18

A Study to Evaluate AEVI-007 in Participants With Adult Onset Still's Disease (clinicaltrials.gov) - P1b | N=12 | Recruiting | Sponsor: Apollo Therapeutics Ltd | Trial completion date: Mar 2022 ➔ Dec 2023 | Trial primary completion date: Mar 2022 ➔ Sep 2023

Trial completion date • Trial primary completion date • Immunology • CRP

"$AVTX Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics https://t.co/PSjsbd4We4" (@stock_titan)

IL18

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b | N=13 | Completed | Sponsor: Avalo Therapeutics, Inc. | Recruiting ➔ Completed | N=30 ➔ 13 | Trial completion date: Jun 2022 ➔ Mar 2022

Enrollment change • Trial completion • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b; N=30; Recruiting; Sponsor: Cerecor Inc; Trial completion date: Aug 2021 ➔ Jun 2022; Trial primary completion date: Aug 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

A Study to Evaluate AEVI-007 in Participants With Adult Onset Still's Disease (clinicaltrials.gov) - P1b; N=12; Recruiting; Sponsor: Cerecor Inc; Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • CRP

A Study to Evaluate AEVI-007 in Participants With Adult Onset Still's Disease (clinicaltrials.gov) - P1b; N=12; Not yet recruiting; Sponsor: Cerecor Inc

Clinical • New P1 trial • CRP

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b; N=30; Recruiting; Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology • CD38

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b; N=30; Not yet recruiting; Sponsor: Aevi Genomic Medicine, LLC, a Cerecor company

Clinical • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

Cerecor Announces FDA Acceptance of Investigational New Drug Application for CERC-007 for Treatment of Relapsed or Refractory Multiple Myeloma (GlobeNewswire) - “Cerecor Inc…announced that its Investigational New Drug Application (IND) to study the use of CERC-007 to treat relapsed or refractory multiple myeloma (MM) has been accepted by the United States Food and Drug Administration (FDA) and is now open. The first study will be a U.S. multicenter Phase 1b clinical trial. Initial data is expected in the first quarter of 2021….The planned Phase 1b clinical trial is a U.S. multicenter, open-label, dose-escalation, sequential group study of CERC-007 as a monotherapy in approximately 30 patients with relapsed or refractory MM.”

Enrollment status • IND • P1 data • Hematological Malignancies • Multiple Myeloma • Oncology

Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma (GlobeNewswire) - “Cerecor Inc…announced that it has dosed its first patient in a Phase 1b clinical trial of CERC-007. CERC-007 is a high affinity, fully human anti-IL-18 monoclonal antibody (mAb) being developed for patients with relapsed or refractory multiple myeloma (MM). The study will determine the recommended Phase 2 dose, safety and preliminary efficacy of CERC-007. The Company anticipates initial data to be reported in the first quarter of 2021.”

P1 data • Trial status • Hematological Malignancies • Multiple Myeloma • Oncology